Chemocentryx, Inc.

Amgen Inc.

Arcus Biosciences, Inc.

Flexus Biosciences, Inc.

Tularik Limited

Bristol-myers Squibb Compnay

Other

Flx Bio, Inc.

Rapt Therapeutics, Inc.

Jay Patrick Powers

Manmohan Reddy Leleti

Penglie Zhang

Pingchen Fan

Hiroko Tanaka

Yandong Li

Ju Yang

Sreenivas Punna

Rebecca M Lui

Juan Carlos Jaen

Jaroslaw Kalisiak

Yibin Zeng

Xuelei Yan

Junfa Fan

Venkat Reddy Mali

Christopher W Lange

Brandon Reid Rosen

Dean R Dragoli

Jeffrey P McMahon

Xi Chen

Dillon Harding Miles

Daqing Sun

Mikhail Zibinsky

James Ross Walker

Viengkham Malathong

Antoni Krasinski

Hunter Paul Shunatona

Hilary Plake Beck

Kenneth Victor Lawson

Maureen Kay Reilly

Maksim Osipov

Trevor T Charvat

Erick Allen Lindsey

Joel Worley Beatty

Ehesan Ul Sharif

Debashis Mandal

Jenna Leigh Jeffrey

Dustin L McMinn

Eric Newcomb

James Aaron Balog

David K Williams

Yosup Rew

Xiao He

Michael R Degraffenreid

Laurent Pierre Paul Debien

Solomon Ungashe

Kevin Lloyd Greenman

Rhiannon Thomas-Tran

Samuel Lawrie Drew

Weifang Shan

Audris Huang

Jay A Markwalder

Emily Charlotte Cherney

Lianfa Li

Guillaume Mata

Anh Thu Tran

Rajinder Paul Singh

William L Thomas

Andrew M K Pennell

Timothy David Cushing

Daniel J Dairaghi

Chao Yu

Cheng Hu

Aaron Robert Novack

Anita Melikian

Weiwei Guo

Edward J Sullivan

Ian Scott Young

Yongli Su

John A Flygare

Xiaoqi Chen

David Juergen Wustrow

Marc Labelle

Zhulun Wang

Jeffrey J Jackson

John Michael Ketcham

Ashkaan Younai

Omar Robles-Resendiz

Dennis X Hu

Benjamin Cohen

Steven P Seitz

Mario G Cardozo

Felix Gonzalez Lopez De Turiso

Liping Zhang

Gregory L Beutner

Jacob A Kaizerman

Sarah Elizabeth Lively

Michael S Bultman

Sergei Kolotuchin

Yu Fan

Qingyian Liu

Francisco Xavier Talamas

Xiaolin Hao

Petinka I Vlahova

Sharada Shenvi Labadie

Chester Chenguang Yuan

Richard J Austin

Jennifer Leigh Nelson

Nianhe Han

Brian Gregory Lucas

The present disclosure relates to amorphous and crystalline forms of (R)—N-(4-chlorophenyl)-2-(1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide and its salts and hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.

Amorphous and crystalline forms of IDO inhibitors

Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.

Inhibitors of ARG1 and/or ARG2

Compound that is an inhibitor of at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Azolopyrimidine for the treatment of cancer-related disorders

Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.

Compounds as inhibitors of AXL

Compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

Inhibitors of adenosine 5'-nucleotidase

Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

2-oxindole compounds

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

The present disclosure is directed to compounds that are inhibitors of HIF-2α having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Inhibitors of HIF-2α and methods of use thereof

Compound that inhibit at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Pyridone A2R antagonists

Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (Ia1′): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.

Substituted tetrahydropyrans as CCR2 modulators

The present invention provides solid forms, solvates and hydrates of 3-[2-amino-6-(1-{[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl}-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl]-2-methylbenzonitrile (Compound I),

Solid forms of an azolopyrimidine compound

The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.

Capsule formulations

Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

CD73 inhibitors

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Immunoregulatory agents

Growing community of inventors

Pacifica, CA, United States of America

Jay Patrick Powers